Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny study tests MRI-Guided radiation for tough prostate cancers

NCT ID NCT03967080

Knowledge-focused Sponsor: East and North Hertfordshire NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This small study looked at whether special MRI scans can help doctors adjust radiation treatment for high-risk prostate cancer. Only 5 men took part, all with aggressive cancer. The goal was to see if the MRI method was reliable enough to guide changes in radiation doses. Because it was so small, the results are just a first step and don't prove the approach works yet.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
adaptive radiotherapy guided by multiparametric MRI
What this could lead to
If successful, this approach could help doctors adjust radiation doses to target tumors more precisely in high-risk prostate cancer.
What could go wrong
This was a very small feasibility study with only 5 participants, so results may not apply broadly. The approach is still experimental and needs much larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

5 people

The number who actually took part.

Started

Feb 2019

Finished

Sep 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

15 male patients scheduled to receive androgen deprivation therapy and external beam radiotherapy for high-risk prostate cancer at Mount Vernon Cancer Centre.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. New diagnosis of high-risk prostate cancer: any of: 1. Gleason score of 8, 9 or 10 2. PSA \> 20 3. T3/4 2. Patient due to receive androgen deprivation therapy (ADT) 3. Prescribed 78Gy/39# external beam radiotherapy 4. Measurable dominant intraprostatic tumour on diagnostic imaging of at least 10mm diameter 5. ≥18 years of age 6. ECOG performance status of 0-1 7. Informed, written and witnessed consent to participate is required. Exclusion Criteria: 1. Patients who are not due to receive androgen deprivation therapy (ADT) 2. Any contraindication to MRI scanning including contraindication to MRI contrast agents 3. Previous radiotherapy to the pelvis 4. Any physical or social reasons that would make attendance for additional visits impossible. 5. Any patient with or planned for prostate fiducial markers. 6. Unable to give informed consent. 7. Patients currently enrolled in an interventional clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for High-risk prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • East and North Hertfordshire NHS Trust

    Northwood, Middlesex, HA6 2RN, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.